Leponex (Clozapine)

Leponex (clozapine) is used in the management of severe psychotic disorders that are resistant to standard antipsychotic therapy.

• Treatment‑resistant schizophrenia: reduces psychotic symptoms and prevents relapse when other antipsychotics have failed.
• Schizoaffective disorder: controls both mood and psychotic components in patients unresponsive to alternative treatments.
• Chronic schizophrenia maintenance: helps maintain symptom control and reduces hospitalization risk in long‑term management.

• Clozapine acts as an antagonist at dopamine D2 receptors and serotonin 5‑HT2A receptors, while also modulating activity at several other neurotransmitter sites such as D4, α‑adrenergic, histamine H1 and muscarinic receptors. This broad receptor profile reduces dopaminergic overactivity and balances serotonergic transmission, leading to improvement of psychotic symptoms in patients who have not responded to more selective antipsychotics.

Clozapine may cause a range of adverse reactions, varying from mild to potentially life‑threatening.

Common Side Effects

• Sedation or drowsiness
• Constipation
• Weight gain
• Drooling (sialorrhea)

Serious or Rare Side Effects

• Agranulocytosis (dangerously low white blood cell count)
• Myocarditis or cardiomyopathy
• Seizures, especially at higher doses

When prescribing clozapine, clinicians should observe several safety measures to minimize risks.

• Baseline blood count: obtain a complete blood count before initiating therapy.
• Regular monitoring: perform weekly white blood cell counts for the first 6 months, then bi‑weekly to monthly as advised.
• Infection vigilance: discontinue if signs of infection or neutropenia develop.
• Concomitant medications: avoid drugs that lower seizure threshold unless necessary.
• Pregnancy and lactation: use only if benefits outweigh potential risks and under specialist supervision.
• Store at room temperature: keep tablets in the original container, protect from moisture and light.

Clozapine interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin): can markedly increase clozapine plasma levels.
• Myelosuppressive agents (e.g., carbamazepine, cyclophosphamide): may exacerbate neutropenia risk.

Moderate Interactions (Monitor Closely)

• CYP1A2 inducers (e.g., smoking, rifampicin): may reduce clozapine concentrations.
• CNS depressants (e.g., benzodiazepines, alcohol): can enhance sedation.
• Anticholinergic drugs (e.g., benztropine): may increase anticholinergic burden.